Japanese Clinical Practice Guideline for Head and Neck Cancer

Nibu, Ken ichi; Hayashi, Ryuichi; Asakage, Takahiro; Ojiri, Hiroya; Kimata, Yoshihiro; Kodaira, Takeshi; Nagao, Toshitaka; Nakashima, Torahiko; Fujii, Takashi; Fujii, Hirofumi; Homma, Akihiro; Matsuura, Kazuto; Monden, Nobuya; Beppu, Teruhiko; Hanai, Nobuhiro; Kirita, Tadaaki; Kamei, Yuzuru; Otsuki, Naoki; Kiyota, Naomi; Zenda, Sadamoto; Omura, Ken; Omori, Koichi; Akimoto, Tetsuo; Kawabata, Kazuyoshi; Kishimoto, Seiji; Kitano, Hiroya; Tohnai, Iwai; Nakatsuka, Takashi

doi:10.1016/j.anl.2017.02.004

Cited by 52 publications

(56 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Surgery and brachytherapy are the major therapies for oral cancer in the T1, T2 and artificial T3 groups (Tumor-Node-Metastasis classification) in clinical practice guidelines for head and neck cancer in Japan ( 42 ). Platinum-based chemotherapy (cisplatin or carboplatin) is used for advanced stage cancer ( 42 , 43 ). In 1978, cisplatin was approved by the Food and Drug Administration (FDA) for oral cancer treatment ( 44 ).…”

Section: Discussionmentioning

confidence: 99%

Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin‑resistant oral cancer CAR cells through intrinsic apoptotic process

Chen

Chiang³

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Cetuximab, an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody (mAb), is a novel targeted therapy for the treatment of patients with oral cancer. Cetuximab can be used in combination with chemotherapeutic agents to prolong the overall survival rates of patients with oral cancer. Curcumin is a traditional Chinese medicine, and it has been demonstrated to have growth-inhibiting effects on oral cancer cells. However, information regarding the combination of cetuximab and curcumin in drug-resistant oral cancer cells is lacking, and its underlying mechanism remains unclear. The purpose of the present study was to explore the oral anticancer effects of cetuximab combined with curcumin on cisplatin-resistant oral cancer CAR cell apoptosis in vitro. The results demonstrated that combination treatment synergistically potentiated the effect of cetuximab and curcumin on the suppression of cell viability and induction of apoptosis in CAR cells. Cetuximab and curcumin combination induced apoptosis and dramatically increased caspase-3 and caspase-9 activities compared with singular treatment. Combination treatment also markedly suppressed the protein expression levels of EGFR and mitogen-activated protein kinases (MAPKs) signaling (phosphorylation of ERK, JNK and p38). The results demonstrated that co-treatment with cetuximab and curcumin exerts synergistic oral anticancer effects on CAR cells through the suppression of the EGFR signaling by regulation of the MAPK pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin‑resistant oral cancer CAR cells through intrinsic apoptotic process

Chen

Chiang³

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…3 : Classified as NPC (keratinizing squamous cell carcinoma or non-keratinizing carcinoma) or non-NPC (squamous cell carcinoma). 4 : We included only those treated with external beam radiotherapy but no brachytherapy or radiosurgery. We included those treated with 1.8-2 Gy/fraction (± 10%) for 66-74 Gy delivered within 1-2 months.…”

Section: Bjrmentioning

confidence: 99%

Effectiveness of tomotherapy v s linear accelerator image-guided intensity-modulated radiotherapy for localized pharyngeal cancer treated with definitive concurrent chemoradiotherapy: a Taiwanese population-based propensity score-matched analysis

Wang

Chien

2018

The British Journal of Radiology

View full text Add to dashboard Cite

For LPC patients treated with definitive CCRT, we found no significant difference in disease control or survival between the T-IMRT and L-IMRT groups. However, further studies, especially randomized trials or studies focusing on other dimensions, such as quality of life, are needed. Advances in knowledge: We provide the first population-based study, as well as the largest study, on the clinical effectiveness of T-IMRT compared with L-IMRT in conjunction with CCRT in LPC patients.

show abstract

“…EGFR is overexpressed in 90% of cases of HNSCC 4. The anti-EGFR antibody cetuximab does not have a major role as a monotherapy, and it is generally combined with other modalities such as radiotherapy or chemotherapy 5. Caution should be taken during the clinical application of cetuximab due to its serious side effects such as interstitial lung disease and infusion reaction (which is unique to antibody therapy) 5.…”

Section: Discussionmentioning

confidence: 99%

“…The anti-EGFR antibody cetuximab does not have a major role as a monotherapy, and it is generally combined with other modalities such as radiotherapy or chemotherapy 5. Caution should be taken during the clinical application of cetuximab due to its serious side effects such as interstitial lung disease and infusion reaction (which is unique to antibody therapy) 5. Afatinib, an irreversible inhibitor of ErbB family proteins (which are receptor tyrosine kinases, structurally related to EGFR), has comparable antitumor efficacy to cetuximab but causes more frequent severe adverse events in patients with R/M HNSCC refractory to platinum-containing regimens 6.…”

Section: Discussionmentioning

confidence: 99%

Good local tumor control but lethal hemorrhage after apatinib treatment for intractable squamous carcinoma of the floor of the mouth: a case report

Zhu¹,

Liu²,

Lv³

et al. 2018

OTT

View full text Add to dashboard Cite

The treatment of repeatedly recurrent carcinoma of the floor of the mouth (FOM) is challenging. There is no standard strategy for such patients with poor physical condition after multiple lines of treatment. Angiogenesis is a key in tumor initiation, growth, and dissemination. Apatinib, a potent tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR2), has been approved for the treatment of late-stage gastric or gastroesophageal junction adenocarcinoma that is resistant to at least two lines of chemotherapy. Its application in intractable FOM squamous carcinoma has never been described before. Herein, we present the case of a heavily treated patient with FOM squamous carcinoma undergoing a third local relapse in the right region of the neck and anterior cervical region. Oral apatinib was administered daily at a dose of 250 mg. There was clear and rapid efficacy that led to complete remission. However, giant, deep ulcers formed due to tumor necrosis. The patient eventually died of massive bleeding resulting from the major cervical vascular rupture caused by tumor necrosis and erosion. This case is novel and instructional, highlighting that apatinib might be effective, with manageable toxicity, for certain patients with refractory head and neck squamous cell carcinoma (HNSCC). The advantages and disadvantages of apatinib should be carefully evaluated, and close surveillance and quick intervention as required are critical to reduce fatal cancer-associated complications. The role of apatinib in recurrent or metastatic HNSCC needs to be clarified by multicenter trials in the near future.

show abstract

Japanese Clinical Practice Guideline for Head and Neck Cancer

Cited by 52 publications

References 13 publications

Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin‑resistant oral cancer CAR cells through intrinsic apoptotic process

Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin‑resistant oral cancer CAR cells through intrinsic apoptotic process

Effectiveness of tomotherapy v s linear accelerator image-guided intensity-modulated radiotherapy for localized pharyngeal cancer treated with definitive concurrent chemoradiotherapy: a Taiwanese population-based propensity score-matched analysis

Good local tumor control but lethal hemorrhage after apatinib treatment for intractable squamous carcinoma of the floor of the mouth: a case report

Contact Info

Product

Resources

About